Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)NewsBilanz/GuVDividende/HVZertifikateDepot/Watchlist
Times + SalesChart-AnalyseAnalysenSchätzungenTermineOptionsscheinemyHome
BörsenplätzeChartvergleichKurszieleVergleichProfilKnock-OutsSenden
OrderbuchRealtime Stuttgart  InsidertradesFonds 
HistorischRealtime PushmyNews im ForumAnleihen
Kaufen
Verkaufen
  • Sprache:
  • Alle
  • DE
  • EN
  • Sortieren:
  • Datum
  • meistgelesen
18.11.14
ONXEO Launches a Rights Issue with Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million) (Businesswire)
13.11.14
Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq® (Businesswire)
06.11.14
Onxeo: Quarterly Information as of September 30, 2014 (Businesswire)
05.11.14
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2014 (Businesswire)
30.10.14
Onxeo S.A.: Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients (Businesswire)
10.10.14
Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium (Businesswire)
03.10.14
Capital Increase in Onxeo as a Result of Employee Warrant Exercise (Businesswire)
02.10.14
Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at September 30, 2014 (Businesswire)
25.09.14
Corporate Governance prize awarded by AGEFI: Onxeo receives "Silver Governance” (Businesswire)
24.09.14
Onxeo announces participation in the Midcap Event On October 2nd and 3rd, 2014 in Paris (Hugin)
24.09.14
Onxeo Announces Participation in the Midcap Event on October 2nd and 3rd, 2014 in Paris (Businesswire)
19.09.14
Onxeo Attends InvestorDagen 2014, the Largest Danish Private Investor Event (Businesswire)
04.09.14
Onxeo: Disclosure of total number of voting rights and number of shares in the capital at August 31, 2014 (Businesswire)
28.08.14
Onxeo Strengthens Beleodaq® Patent Protection in the U.S. Until 2027 (Businesswire)
01.08.14
Onxeo SA: Key milestones and consolidated accounts First six months 2014 (Businesswire)
24.07.14
BioAlliance Pharma: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen (Businesswire)
23.07.14
The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 (Businesswire)
21.07.14
BioAlliance Pharma Announces the Launch of Sitavig® in the United States by Its Partner Innocutis (Businesswire)
18.07.14
BioAlliance Pharma Strengthens Its Financial Resources with the Support of Its Top Shareholder (Businesswire)
03.07.14
BioAlliance Pharma: FDA approval of Beleodaq™ (belinostat) (Businesswire)
03.07.14
BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at June 30, 2014 (Businesswire)
30.06.14
Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo (Businesswire)
25.06.14
BioAlliance Pharma : Execution of a License Agreement with EMS for Sitavig® in Brazil (Businesswire)
20.06.14
Merger Plan with Topotarget: BioAlliance Pharma Has Received Pre-Approval for the Secondary Listing of the Shares of the Merged Company on NASDAQ OMX Copenhagen (Businesswire)
10.06.14
BioAlliance Pharma Strengthens Livatag® pAtent Protection in Japan Until 2032 (Businesswire)
10.06.14
BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at May 31, 2014 (Businesswire)
21.05.14
Definitive Merger Plan between BioAlliance Pharma and Topotarget (Businesswire)
19.05.14
BioAlliance Pharma SA: Livatag® Receives Fast Track Designation From the FDA for the Treatment of Primary Liver Cancer (Businesswire)
12.05.14
BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2014 (Businesswire)
05.05.14
BioAlliance Pharma Announces Major Achievements on Validive® (Businesswire)
30.04.14
BioAlliance Pharma SA: Quarterly information as of March 31, 2014 (Businesswire)
29.04.14
BioAlliance Pharma Publishes Its First Shareholder Newsletter (Businesswire)
16.04.14
BioAlliance Pharma and Topotarget Enter into Merger Agreement to Create a Leading Orphan Oncology Company (Businesswire)
14.04.14
BioAlliance Pharma Announces a New Positive DSMB Recommendation to Continue Its Phase III Clinical Trial with Livatag® in Primary Liver Cancer (Businesswire)
08.04.14
BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions (Businesswire)
08.04.14
BioAlliance Pharma SA : Publication of the 2013 Registration Document (Businesswire)
03.04.14
BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2014 (Businesswire)
02.04.14
BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea (Businesswire)
01.04.14
BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig® (Businesswire)
31.03.14
BioAlliance Pharma Collaborates with Penn Pharma on the Industrial Development of Validive® (Businesswire)
Seite: 1234

Bioalliance PharmaAct Nom Cat-P News

Bioalliance PharmaAct Nom Cat-P News: auf dieser Seite finden Sie alle Bioalliance PharmaAct Nom Cat-P News und Nachrichten zur Bioalliance PharmaAct Nom Cat-P Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bioalliance PharmaAct Nom Cat-P News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bioalliance PharmaAct Nom Cat-P News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Meistgelesene Bioalliance PharmaAct Nom Cat-P News

Bioalliance PharmaAct Nom Cat-P Peer Group News

Keine Nachrichten gefunden.